NH drug info case begins

Share this article:
IMS Health and Verispan will seek to protect the right to market prescription data from pharmacies in a case beginning this week. The research firms are bringing the case in US District Court in New Hampshire in the hope of striking down a law that took effect in the state last August, the Prescription Privacy Protection Act. The case’s outcome could set a precedent for states such as Nebraska, Nevada and Missouri, which have introduced copycat bills. New York is expected to do so this year. By banning the commercial use of prescription audit data, the act is designed to stop pharmaceutical sales people from influencing physicians’ medical decisions as well as help cut healthcare costs by leading to prescribing of less expensive drugs, say proponents. Under an exemption in the law, organizations can use the information as long as they do not profit from it. IMS and Verispan argue that the act restricts the flow of essential prescriber information and that it violates First Amendment free-speech protections. New Hampshire Rep. Cindy Rosenwald introduced the bill after her husband, a cardiologist, complained of being targeted by a sales rep.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.